Serum 25(OH)D Levels, Supplemental Vitamin D, and Parathyroid Hormone Levels in Premature Infants
| Status: | Completed |
|---|---|
| Conditions: | Women's Studies |
| Therapuetic Areas: | Reproductive |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 9/15/2017 |
| Start Date: | January 2012 |
| End Date: | July 2013 |
The specific aims of this study are to determine levels of vitamin D supplementation to
achieve goal serum 25(OH)D levels of 30 ng/mL, and to define serum 25(OH)D levels required to
achieve suppression of parathyroid hormone in preterm newborn infants hospitalized in the
Nebraska Medical Center Newborn Intensive Care Nursery (NICU). In this randomized, controlled
trial, infants 23 weeks gestational age or greater will be randomized to two different levels
of vitamin D supplementation: 400 IU vitamin D3/day, or 800 IU vitamin D3/day. As an
exploratory aim, vitamin D binding protein levels (VDBP) will also be quantified in these
infants.
achieve goal serum 25(OH)D levels of 30 ng/mL, and to define serum 25(OH)D levels required to
achieve suppression of parathyroid hormone in preterm newborn infants hospitalized in the
Nebraska Medical Center Newborn Intensive Care Nursery (NICU). In this randomized, controlled
trial, infants 23 weeks gestational age or greater will be randomized to two different levels
of vitamin D supplementation: 400 IU vitamin D3/day, or 800 IU vitamin D3/day. As an
exploratory aim, vitamin D binding protein levels (VDBP) will also be quantified in these
infants.
Inclusion Criteria:
- NICU hospitalized infants
- 23-32 weeks gestation
Exclusion Criteria:
- congential anomalies
- disorders of calcium metabolism
- inborn error of metabolism
- kidney disease
- liver disease
- use of steroids
We found this trial at
1
site
Nebraska Medical Center Formed in 1997 by combining the operations of University Hospital, Bishop Clarkson...
Click here to add this to my saved trials
